Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front‐line regimens using the SEER‐Medicare data

The landscape of treatment for multiple myeloma (MM) has significantly changed over the last decade due to novel agents that have shown superiority in efficacy such as proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) over traditional therapies. However, the real‐world utilization of th...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Cancer medicine (Malden, MA) Ročník 9; číslo 2; s. 626 - 639
Hlavní autoři:	Goto, Daisuke, Khairnar, Rahul, Yared, Jean A., Yong, Candice, Romanus, Dorothy, Onukwugha, Eberechukwu, Slejko, Julia F.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States John Wiley & Sons, Inc 01.01.2020 John Wiley and Sons Inc Wiley
Témata:	Age Aged Aged, 80 and over Algorithms Alkylating agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bone lesions Cancer therapies Clinical Cancer Research Clinical trials Datasets Disease elderly patients Epidemiology Female Follow-Up Studies Geriatrics Humans Hypercalcemia Immunomodulation Immunomodulators immunomodulatory drugs (IMiDs) Immunosuppressive agents Male Medicare Medicare - statistics & numerical data Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - epidemiology Multiple Myeloma - pathology Original Research Patients Prognosis Proteasome inhibitors Renal failure Retrospective Studies SEER Program - statistics & numerical data SEER‐Medicare Stem cell transplantation Stem cells Studies Survival Rate systemic treatment United States - epidemiology United States United States > US elderly patients proteasome inhibitors multiple myeloma systemic treatment SEER-Medicare immunomodulatory drugs (IMiDs)
ISSN:	2045-7634, 2045-7634
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!